Margriet den Boer

Summary

Publications

  1. ncbi request reprint Treatment options for visceral leishmaniasis
    Margriet den Boer
    Campaign for Access to Essential Medicines, Medecins Sans Frontieres, Rue Lausanne 78 CP 116 CH 1211, Geneva 21, Switzerland
    Expert Rev Anti Infect Ther 4:187-97. 2006
  2. ncbi request reprint A comparison of miltefosine and sodium stibogluconate for treatment of visceral leishmaniasis in an Ethiopian population with high prevalence of HIV infection
    Koert Ritmeijer
    Medecins Sans Frontieres Holland, Amsterdam, The Netherlands
    Clin Infect Dis 43:357-64. 2006
  3. ncbi request reprint Liposomal amphotericin B for the treatment of visceral leishmaniasis
    Caryn Bern
    Division of Parasitic Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA
    Clin Infect Dis 43:917-24. 2006
  4. pmc The relationship between leishmaniasis and AIDS: the second 10 years
    Jorge Alvar
    Control of Neglected Tropical Diseases, World Health Organization, 20 Avenue Appia, CH 1211 Geneva 27, Switzerland
    Clin Microbiol Rev 21:334-59, table of contents. 2008

Detail Information

Publications4

  1. ncbi request reprint Treatment options for visceral leishmaniasis
    Margriet den Boer
    Campaign for Access to Essential Medicines, Medecins Sans Frontieres, Rue Lausanne 78 CP 116 CH 1211, Geneva 21, Switzerland
    Expert Rev Anti Infect Ther 4:187-97. 2006
    ..No new drugs are currently in the early stages of development. There are good reasons for the use of combination therapy; to prevent further development of resistance against the limited therapeutic options available...
  2. ncbi request reprint A comparison of miltefosine and sodium stibogluconate for treatment of visceral leishmaniasis in an Ethiopian population with high prevalence of HIV infection
    Koert Ritmeijer
    Medecins Sans Frontieres Holland, Amsterdam, The Netherlands
    Clin Infect Dis 43:357-64. 2006
    ..Oral miltefosine has been proven to be safe and effective in the treatment of Indian VL but has not been studied in Africa or in persons with HIV and VL coinfection...
  3. ncbi request reprint Liposomal amphotericin B for the treatment of visceral leishmaniasis
    Caryn Bern
    Division of Parasitic Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA
    Clin Infect Dis 43:917-24. 2006
    ..The public health community should work to broaden access to preferential liposomal amphotericin B pricing by public sector VL treatment programs...
  4. pmc The relationship between leishmaniasis and AIDS: the second 10 years
    Jorge Alvar
    Control of Neglected Tropical Diseases, World Health Organization, 20 Avenue Appia, CH 1211 Geneva 27, Switzerland
    Clin Microbiol Rev 21:334-59, table of contents. 2008
    ..Based on the previous experience of 20 years of coinfection in Europe, this review focuses on the management of Leishmania-HIV-coinfected patients in low-income countries where leishmaniasis is endemic...